leukemia

Blood-Based MRD Testing Identifies AML Patients at Risk of Relapse After Stem Cell Transplant

European Medicine Agency's CHMP Recommends Tibsovo for IDH1-Mutated AML, Bile Duct Cancer

Kura Oncology Begins Phase II Ziftomenib Trial in NPM1-Mutant Acute Myeloid Leukemia

Actinium Pharmaceuticals, NCI Ink Research Agreement on Targeted Radiopharmaceutical

Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial

Aptose Biosciences Begins Expansion Trial of Tuspetinib in TP53, FLT3-Mutant AML

BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data

Theseus Reveals Development Milestones for its Precision Oncology Programs in 2023

Pharmacotyping Links Childhood Leukemia Subtypes to Treatment Response

OneChain Immunotherapeutics to Launch CD1a-Targeting CAR T-Cell Therapy Trial in T-Cell Leukemia

Ordaōs, Yatiri Bio Ink Deal to Discover, Develop More Personalized Drugs for AML

SeekIn Receives CE-IVD Mark for Leukemia Cancer Mutation Detection Kit

Envisagenics, Cancer Research UK, Queen Mary University Collaborate on AML Drug R&D

Daiichi Sankyo Transfers Rights to Market Yescarta in Japan to Gilead Sciences

FDA Approves Rigel Pharmaceuticals' Rezlidhia for IDH1-Mutant AML

Takeda to Discuss Positive Phase III Iclusig Data in Upfront ALL With Regulators